Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Pareto Securities AB and Swedbank AB (publ) in connection with a bond issue with a framework amount of up to MSEK 700
Mandate

Vinge has advised Pareto Securities AB and Swedbank AB (publ) in connection with a bond issue with a framework amount of up to MSEK 700

December 18, 2017 Banking and Finance

Vinge has advised Pareto Securities AB and Swedbank AB (publ) in connection with a bond issue with a framework amount of up to MSEK 700 senior unsecured floating rate bonds, issued by Offentliga Hus i Norden AB (publ) (”Offentliga Hus”) on 15 December 2017.

Pareto Securities AB and Swedbank AB (publ) have acted as arrangers and Swedbank AB (publ) also acted as issuing agent. The bonds have a tenor of three and a half years and a floating interest rate of three-months STIBOR plus a margin of 7.00 per cent.
 
The proceeds from the bond issue will be applied towards financing property acquisitions and other general corporate purposes. Offentliga Hus intends to apply for the bonds to be listed on Nasdaq Stockholm.
 
Vinges team consisted inter alia of Louise Brorsson Salomon, Lionardo Ojeda and Sara Osman.

Related

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

 Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

 Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026